Climb Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Climb Bio, Inc. (Nasdaq: CLYM) on June 18, 2025, reporting events occurring on June 12, 2025, and June 16, 2025. The filing addresses significant changes to the Company's senior financial leadership, specifically the appointment of a new Principal Financial Officer (PFO) and Principal Accounting Officer (PAO), and the resignation of the former Chief Accounting Officer.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Appointment of New CFO: The Board appointed Cindy Driscoll as Senior Vice President, Finance, PFO, and PAO, effective June 17, 2025.
- Resignation of Former CAO: Emily Pimblett, Senior Vice President, Finance and Chief Accounting Officer, notified the Company of her resignation effective June 30, 2025. She ceased serving as PAO upon Driscoll's appointment.
- Role Transition: Aoife Brennan, President and CEO, ceased serving as interim PFO effective June 17, 2025, but continues as Principal Executive Officer.
Compensation, Outlook, and Risks
Compensation Package for Cindy Driscoll:
- Base Salary: $355,000 per year.
- Discretionary Bonus: Eligible for up to 35.0% of annualized base salary.
- Equity Grant: Stock option to purchase 200,000 shares of common stock at the closing price on the Effective Date. Vesting schedule: 25% on the first anniversary, with the remainder vesting in 36 equal monthly installments.
- Severance Provisions:
- Standard Termination (No Cause/Good Reason): 6 months base salary + target bonus (if employed >12 months) or 3 months base salary + target bonus (if employed <12 months), plus COBRA coverage and acceleration of equity vesting for the 3-month period following termination.
- Change in Control Termination: 9 months base salary + target bonus + unpaid prior year bonus, plus 9 months COBRA coverage and full acceleration of all unvested time-based equity awards.
Risks and Contingencies: The Company has entered into an indemnification agreement with Ms. Driscoll, potentially obligating the Company to cover legal expenses, judgments, and settlements arising from her service. There are no reported related party transactions or family relationships between Ms. Driscoll and Company directors/officers.
Investor Verification Checklist
- Verify the closing stock price on June 17, 2025, to calculate the exercise price of the 200,000 share option granted to Ms. Driscoll.
- Review the Company's 2025 Inducement Plan to confirm the terms under which the equity grant was authorized.
- Monitor the transition period between June 17 and June 30, 2025, to ensure continuity of financial reporting during the overlap of the new and departing officers.
- Assess the impact of the new compensation structure on future operating expenses and potential dilution from the stock option grant.